Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cancer Drug Targets
  4. Fast Track Articles
  5. Fast Track Article
image of Disulfiram-Copper Potentiates Anticancer Efficacy of Standard Chemotherapy Drugs in Bladder Cancer Animal Model through ROS-Autophagy-Ferroptosis Signalling Cascade

Abstract

Background

Cost-effective management of Urinary Bladder Cancer (UBC) is an unmet need.

Aims

Our study aims to demonstrate the efficacy of a drug repurposing strategy by using disulfiram (DSF) and copper gluconate (Cu) as an add-on treatment combination to traditional GC-based chemotherapy against N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced UBC mice (C57J) model.

Methods

Male C57BL/6J mice were given 0.05% BBN in drinking water ad libitum, and tumour formation was verified by histological and physical evaluation. Animals were subsequently divided into eight groups and received treatment with different drug combinations. Control animals received only vehicle (DMSO). At the end of the treatment schedule, the bladder tumour was excised and further used to check the expression (mRNA and protein) of ALDH1 isoenzymes using qRT-PCR, western blot, and IHC methods. Autophagy induction was assessed by quantifying the expression of LC3B and SQSTM1/p62 proteins through IHC. Biochemical analysis of superoxide dismutase (SOD), reduced glutathione (GSH), and lipid peroxidation levels in the freshly isolated tumours was performed to check the alterations in the antioxidant system caused by combination treatment.

Results

We observed significant induction of an invasive form of bladder cancer in the mice after nineteen weeks of BBN exposure. The animals began exhibiting early indications of inflammatory alterations as early as the sixth week following BBN treatment. Furthermore, the wet bladder weight and overall tumour burden were significantly decreased (p< 0.0001) by DSF-Cu co-treatment in addition to the GC-based chemotherapy. Real-time PCR analysis revealed that treatment with disulfiram and copper gluconate significantly decreased (p<0.0001) the mRNA expression of ALDH1 isoenzymes. Comparing the triple drug combination group (GC+DSF-Cu) to the untreated mice, a significant rise in LC3B puncta (p<0.0001) and a decrease in P62/SQSTM1 (p=0.0002) were noted, indicating the induction of autophagy flux in the add-on group. When GC+DSF-Cu treated mice were compared to the untreated tumour group, a substantial decrease in ALDH1/2 protein expression was observed (p= 0.0029 in IHC and p<0.0001 in western blot). Lipid peroxidation was significantly higher (p<0.0001) in the triple drug combination group than in untreated mice. There was a simultaneous decrease in reduced glutathione (GSH) and enzyme superoxide dismutase (SOD) levels (p<0.0001), which strongly suggests the generation of reactive oxygen species and induction of ferroptotic cell death in the add-on therapy group. Additionally, in both IHC and western blot assays, ALDH1A3 expression was found to be significantly increased (p=0.0033, <0.0001 respectively) in GC+DSF-Cu treated mice relative to the untreated group, suggesting a potential connection between the ferroptosis pathway and ALDH1A3 overexpression.

Conclusion

It was found that disulfiram with copper treatment inhibits bladder tumour growth through ferroptosis-mediated ROS induction, which further activates the process of autophagy. Our results prove that DSF-Cu can be an effective add-on therapy along with the standard chemotherapy drugs for the treatment of UBC.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096325879240815105227
2024-09-25
2025-01-18

  • From This Site

    /content/journals/ccdt/10.2174/0115680096325879240815105227
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Saginala K. Barsouk A. Aluru J.S. Rawla P. Padala S.A. Barsouk A. Epidemiology of Bladder Cancer. 2020 10.3390/medsci8010015
    [Google Scholar]
  2. Sanli O. Dobruch J. Knowles M.A. Burger M. Alemozaffar M. Nielsen M.E. Lotan Y. Bladder cancer. Nat. Rev. Dis. Primers 2017 3 1 17022 10.1038/nrdp.2017.22 28406148
    [Google Scholar]
  3. Esteban-Villarrubia J. Torres-Jiménez J. Bueno-Bravo C. García-Mondaray R. Subiela J.D. Gajate P. Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer. Cancers (Basel) 2023 15 3 566 10.3390/cancers15030566 36765525
    [Google Scholar]
  4. Wołącewicz M. Hrynkiewicz R. Grywalska E. Suchojad T. Leksowski T. Roliński J. Niedźwiedzka-Rystwej P. Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. Cancers (Basel) 2020 12 5 1181 10.3390/cancers12051181 32392774
    [Google Scholar]
  5. Gakis G. Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. Eur. Urol. Focus 2020 6 4 632 638 10.1016/j.euf.2020.01.007 31987763
    [Google Scholar]
  6. Pichler R. Loidl W. Pichler M. High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer. Transl. Androl. Urol. 2018 7 S6 Suppl. 6 S738 S740 10.21037/tau.2018.08.15 30687612
    [Google Scholar]
  7. Ireson C.R. Alavijeh M.S. Palmer A.M. Fowler E.R. Jones H.J. The role of mouse tumour models in the discovery and development of anticancer drugs. Br. J. Cancer 2019 121 2 101 108 10.1038/s41416‑019‑0495‑5 31231121
    [Google Scholar]
  8. Korac-Prlic J. Degoricija M. Vilović K. Vujević S. Terzić J. BBN-driven urinary bladder cancer mouse model. Methods Cell Biol. 2021 163 77 92 10.1016/bs.mcb.2020.10.020 33785170
    [Google Scholar]
  9. Degoricija M. Korac-Prlic J. Vilovic K. Ivanisevic T. Haupt B. Palada V. Petkovic M. Karaman I. Terzic J. The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice. J. Transl. Med. 2019 17 1 394 10.1186/s12967‑019‑02146‑5 31779626
    [Google Scholar]
  10. K W To K. Cho W.C.S. K KWT Drug Repurposing for Cancer Therapy in the Era of Precision Medicine. Curr. Mol. Pharmacol. 2022 15 7 895 903 10.2174/1874467215666220214104530 35156588
    [Google Scholar]
  11. Lu Y. Pan Q. Gao W. Pu Y. Luo K. He B. Gu Z. Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens. Biomaterials 2022 281 121335 10.1016/j.biomaterials.2021.121335 34979419
    [Google Scholar]
  12. Kannappan V. Ali M. Small B. Rajendran G. Elzhenni S. Taj H. Wang W. Dou Q.P. Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents. Front. Mol. Biosci. 2021 8 741316 10.3389/fmolb.2021.741316 34604310
    [Google Scholar]
  13. Livak K.J. Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 25 4 402 408 10.1006/meth.2001.1262 11846609
    [Google Scholar]
  14. Ohkawa H. Ohishi N. Yagi K. Reaction of linoleic acid hydroperoxide with thiobarbituric acid. J. Lipid Res. 1978 19 8 1053 1057 10.1016/S0022‑2275(20)40690‑X 103988
    [Google Scholar]
  15. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Anal. Biochem. 1969 27 3 502 522 10.1016/0003‑2697(69)90064‑5 4388022
    [Google Scholar]
  16. Tipple T.E. Rogers L.K. Methods for the determination of plasma or tissue glutathione levels. Methods Mol. Biol. 2012 889 315 324 10.1007/978‑1‑61779‑867‑2_20 22669674
    [Google Scholar]
  17. Durak I. Yurtarslanl Z. Canbolat O. Akyol Ö. A methodological approach to superoxide dismutase (SOD) activity assay based on inhibition of nitroblue tetrazolium (NBT) reduction. Clin. Chim. Acta 1993 214 1 103 104 10.1016/0009‑8981(93)90307‑P 8453769
    [Google Scholar]
  18. Irving C.C. Tice A.J. Murphy W.M. Inhibition of N-n-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in rats by administration of disulfiram in the diet. Cancer Res. 1979 39 8 3040 3043 455288
    [Google Scholar]
  19. Song H.K. Hwang D.Y. Use of C57BL/6N mice on the variety of immunological researches. Lab. Anim. Res. 2017 33 2 119 123 10.5625/lar.2017.33.2.119 28747977
    [Google Scholar]
  20. Ding J. Xu D. Pan C. Ye M. Kang J. Bai Q. Qi J. Current animal models of bladder cancer: Awareness of translatability (Review). Exp. Ther. Med. 2014 8 3 691 699 10.3892/etm.2014.1837 25120584
    [Google Scholar]
  21. Kakizoe T. Development and progression of urothelial carcinoma. Cancer Sci. 2006 97 9 821 828 10.1111/j.1349‑7006.2006.00264.x 16822297
    [Google Scholar]
  22. Amponsa V.O. Shuman L. Ellis J. Wang E. Walter V. Owens R.G. Zaleski M. Warrick J.I. Raman J.D. DeGraff D.J. Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274/Pdl-1 expression. Am. J. Clin. Exp. Urol. 2019 7 3 139 152 31317053
    [Google Scholar]
  23. Fujii K. Odashima S. Okada M. Induction of tumours by administration of N-dibutylnitrosamine and derivatives to infant mice. Br. J. Cancer 1977 35 5 610 614 10.1038/bjc.1977.95 861148
    [Google Scholar]
  24. Perše M. Cisplatin Mouse Models: Treatment, Toxicity and Translatability. Biomedicines 2021 9 10 1406 10.3390/biomedicines9101406 34680523
    [Google Scholar]
  25. Wu W. Wu Y. Mayer K. von Rosenstiel C. Schecker J. Baur S. Würstle S. Liesche-Starnecker F. Gempt J. Schlegel J. Lipid Peroxidation Plays an Important Role in Chemotherapeutic Effects of Temozolomide and the Development of Therapy Resistance in Human Glioblastoma. Transl. Oncol. 2020 13 3 100748 10.1016/j.tranon.2020.100748 32087559
    [Google Scholar]
  26. Chen X. Comish P.B. Tang D. Kang R. Characteristics and Biomarkers of Ferroptosis. Front. Cell Dev. Biol. 2021 9 637162 10.3389/fcell.2021.637162 33553189
    [Google Scholar]
  27. Wu Y. Kram H. Gempt J. Liesche-Starnecker F. Wu W. Schlegel J. ALDH1-Mediated Autophagy Sensitizes Glioblastoma Cells to Ferroptosis. Cells 2022 11 24 4015 10.3390/cells11244015 36552781
    [Google Scholar]
  28. Hu Y. Qian Y. Wei J. Jin T. Kong X. Cao H. Ding K. The Disulfiram/Copper Complex Induces Autophagic Cell Death in Colorectal Cancer by Targeting ULK1. Front. Pharmacol. 2021 12 752825 10.3389/fphar.2021.752825 34887757
    [Google Scholar]
  29. Majera D. Skrott Z. Chroma K. Merchut-Maya J.M. Mistrik M. Bartek J. Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway. Cells 2020 9 2 469 10.3390/cells9020469 32085572
    [Google Scholar]
  30. Anderson D.J. Le Moigne R. Djakovic S. Kumar B. Rice J. Wong S. Wang J. Yao B. Valle E. Kiss von Soly S. Madriaga A. Soriano F. Menon M.K. Wu Z.Y. Kampmann M. Chen Y. Weissman J.S. Aftab B.T. Yakes F.M. Shawver L. Zhou H.J. Wustrow D. Rolfe M. Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. Cancer Cell 2015 28 5 653 665 10.1016/j.ccell.2015.10.002 26555175
    [Google Scholar]
  31. Pankiv S. Clausen T.H. Lamark T. Brech A. Bruun J.A. Outzen H. Øvervatn A. Bjørkøy G. Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 2007 282 33 24131 24145 10.1074/jbc.M702824200 17580304
    [Google Scholar]
  32. Nie D. Chen C. Li Y. Zeng C. Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis. Blood Science 2022 4 3 152 154 10.1097/BS9.0000000000000117 36518588
    [Google Scholar]
  33. Qiu C. Zhang X. Huang B. Wang S. Zhou W. Li C. Li X. Wang J. Yang N. Disulfiram, a Ferroptosis Inducer, Triggers Lysosomal Membrane Permeabilization by Up-Regulating ROS in Glioblastoma. OncoTargets Ther. 2020 13 10631 10640 10.2147/OTT.S272312 33116640
    [Google Scholar]
  34. von Krusenstiern A.N. Robson R.N. Qian N. Qiu B. Hu F. Reznik E. Smith N. Zandkarimi F. Estes V.M. Dupont M. Hirschhorn T. Shchepinov M.S. Min W. Woerpel K.A. Stockwell B.R. Identification of essential sites of lipid peroxidation in ferroptosis. Nat. Chem. Biol. 2023 19 6 719 730 10.1038/s41589‑022‑01249‑3 36747055
    [Google Scholar]
  35. Cheng Y. Song Y. Chen H. Li Q. Gao Y. Lu G. Luo C. Ferroptosis Mediated by Lipid Reactive Oxygen Species: A Possible Causal Link of Neuroinflammation to Neurological Disorders. Oxid. Med. Cell. Longev. 2021 2021 1 13 10.1155/2021/5005136 34725564
    [Google Scholar]
  36. Ren X. Li Y. Zhou Y. Hu W. Yang C. Jing Q. Zhou C. Wang X. Hu J. Wang L. Yang J. Wang H. Xu H. Li H. Tong X. Wang Y. Du J. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis. Redox Biol. 2021 46 102122 10.1016/j.redox.2021.102122 34482117
    [Google Scholar]
  37. Li C. Zhou S. Chen C. Zhu L. Li S. Song Z. Liang J. Tang C. Xu N. Liu T. Liu S. DDTC-Cu(I) based metal-organic framework (MOF) for targeted melanoma therapy by inducing SLC7A11/GPX4-mediated ferroptosis. Colloids Surf. B Biointerfaces 2023 225 113253 10.1016/j.colsurfb.2023.113253 36934611
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096325879240815105227
Loading
Disulfiram-Copper Potentiates Anticancer Efficacy of Standard Chemotherapy Drugs in Bladder Cancer Animal Model through ROS-Autophagy-Ferroptosis Signalling Cascade
Bentham Science Publishers ; https://doi.org/10.2174/0115680096325879240815105227
/content/journals/ccdt/10.2174/0115680096325879240815105227
/content/journals/ccdt/10.2174/0115680096325879240815105227
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) ; ferroptosis ; drug repurposing ; urinary bladder cancer ; autophagy ; reactive oxygen species

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test